The warrants of series TO3 were issued in connection with the rights issue announced on 20 February 2024, with a subscription period that ended on 17 April 2024. Each warrant entitles the holder to subscribe for one (1) new share in Spermosens at a subscription price of 0.13 SEK. The exercise period for the warrants runs from 17 February 2025 to 3 March 2025.

The subscription price of 0.13 SEK was determined before the issuance of new shares in the rights issue carried out in November 2024. Based on the current share price, the warrants are out of the money, meaning that the subscription price exceeds the market price of the Company's share.

Upon full exercise of the TO3 warrants, the Company’s share capital would increase by 277,043.936 SEK, and the dilution for existing shareholders would amount to approximately 32.8 percent, based on the total number of shares at the time of the Memorandum. The warrants are subject to customary adjustment terms in connection with new share issues or similar events.

For further information, please contact:
Tore Duvold, CEO
E-mail: info@spermosens.com